Hikaru Saito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hikaru Saito has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Hiroto Tashiro
Department of Chemistry, Faculty of Science, Niigata University, Niigata 950-2181, Japan
1 shared publication - Kazuhiro Furukawa
Department of Chemistry, Faculty of Science, Niigata University, Niigata 950-2181, Japan
1 shared publication - Kazuki Yamazaki
Department of Chemistry, Faculty of Science, Niigata University, Niigata 950-2181, Japan
1 shared publication - Keisuke Baba
Department of Chemistry, Faculty of Science, Niigata University, Niigata 950-2181, Japan
1 shared publication - Masataka Mizunuma
Department of Chemistry, Faculty of Science, Niigata University, Niigata 950-2181, Japan
1 shared publication - Megumi Ikeura
Department of Chemistry, Faculty of Science, Niigata University, Niigata 950-2181, Japan
1 shared publication
Latest Publications
- Open Access
Development of Antibody-like Proteins Targeting the Oncogenic Ser/Thr Protein Phosphatase PPM1D
PPM1D, a protein Ser/Thr phosphatase, is overexpressed in various cancers and functions as an oncogenic protein by inactivating the p53 pathway. Therefore, molecules that bind PPM1D are expected to be useful anti-cancer agents. In this study, we constructed a phage display library based on the antibody-like small molecule protein adnectin and screened for PPM1D-specific binding molecules. We identified two adnectins, PMDB-1 and PMD-24, that bind PPM1D specific B-loop and PPM1D430 as targets, respectively. Specificity analyses of these recombinant proteins using other Ser/Thr protein phosphatases showed that these molecules bind to only PPM1D. Expression of PMDB-1 in breast cancer-derived MCF-7 cells overexpressing endogenous PPM1D stabilized p53, indicating that PMDB-1 functions as an inhibitor of PPM1D. Furthermore, MTT assay exhibited that MCF-7 cells expressing PMDB-1 showed inhibition of cell proliferation. These data suggest that the adnectin PMDB-1 identified in this study can be used as a lead compound for anti-cancer drugs targeting intracellular PPM1D.
Open AccessDevelopment of Antibody-like Proteins Targeting the Oncogenic Ser/Thr Protein Phosphatase PPM1D
PPM1D, a protein Ser/Thr phosphatase, is overexpressed in various cancers and functions as an oncogenic protein by inactivating the p53 pathway. Therefore, molecules that bind PPM1D are expected to be useful anti-cancer agents. In this study, we constructed a phage display library based on the antibody-like small molecule protein adnectin and screened for PPM1D-specific binding molecules. We identified two adnectins, PMDB-1 and PMD-24, that bind PPM1D specific B-loop and PPM1D430 as targets, respectively. Specificity analyses of these recombinant proteins using other Ser/Thr protein phosphatases showed that these molecules bind to only PPM1D. Expression of PMDB-1 in breast cancer-derived MCF-7 cells overexpressing endogenous PPM1D stabilized p53, indicating that PMDB-1 functions as an inhibitor of PPM1D. Furthermore, MTT assay exhibited that MCF-7 cells expressing PMDB-1 showed inhibition of cell proliferation. These data suggest that the adnectin PMDB-1 identified in this study can be used as a lead compound for anti-cancer drugs targeting intracellular PPM1D.